What inhaled corticosteroid (ICS) and dosing regimen should be used as first‑line controller therapy for persistent asthma?

First-Line Inhaled Corticosteroid for Persistent Asthma

Start with low-dose fluticasone propionate 100-250 mcg/day or budesonide 200-400 mcg/day, administered twice daily via metered-dose inhaler with spacer, as this achieves 80-90% of maximum therapeutic benefit with minimal systemic effects. 1

Recommended Starting Regimens by Age

Adults and adolescents ≥12 years:

• Fluticasone propionate 100-250 mcg/day divided twice daily 1
• Budesonide 200-400 mcg/day divided twice daily 1
• Beclomethasone dipropionate 200-500 mcg/day divided twice daily 1
• All regimens should be combined with as-needed short-acting beta-agonist (SABA) for symptom relief 1

Children 5-11 years:

• Low-dose ICS at age-appropriate dosing (e.g., fluticasone 100 mcg twice daily) 1
• This is the preferred Step 2 treatment for mild persistent asthma in this age group 1

Children <5 years:

• Daily low-dose ICS is preferred and more effective than cromolyn or leukotriene receptor antagonists 1

Why Low-Dose ICS Is Optimal

The evidence strongly supports starting at low doses rather than higher doses:

• Low-dose ICS provides 80-90% of the maximum achievable therapeutic benefit 1, 2
• Starting with high-dose ICS offers no clinically meaningful advantage over low-dose, with only a 5% improvement in FEV1 1
• Higher doses increase risk of systemic adverse effects without proportional clinical benefit 3
• Network meta-analysis of 31 randomized trials found high starting doses had no additional benefit in 3 of 4 efficacy parameters compared to low doses 3

Essential Delivery Technique

Always prescribe a spacer or valved holding chamber with metered-dose inhalers to:

• Reduce oropharyngeal deposition and minimize local side effects like thrush 1
• Increase lung deposition 1

Instruct patients to rinse mouth and spit after each inhalation to further reduce local adverse effects 1

No Clinically Meaningful Differences Between ICS Types

When used at equivalent doses, there are no clinically meaningful differences in efficacy among various ICS formulations 1. The choice can be based on:

• Device availability and patient ability to use it correctly 4
• Cost considerations 1
• Pregnancy status: budesonide is the only Pregnancy Category B ICS; all others are Category C 5

When to Assess Response and Step Up

Evaluate treatment response at 2-6 weeks:

• If no clear clinical benefit within 4-6 weeks, stop ICS and consider alternative therapies or diagnoses 1
• If asthma remains uncontrolled after 2-6 weeks on low-dose ICS, add a long-acting beta-agonist (LABA) to the same low-dose ICS rather than increasing ICS dose alone 1

The combination of low-dose ICS + LABA provides:

• Greater improvement in lung function (weighted mean difference ≈0.12 L/sec) 1
• Better symptom control 1
• Greater exacerbation reduction compared to doubling ICS dose 1

Critical Safety Warning About LABAs

LABAs must NEVER be used as monotherapy for asthma because:

• Monotherapy increases risk of severe exacerbations and asthma-related deaths 1, 6
• LABAs must always be combined with ICS in a single inhaler or as separate inhalers 1
• This is supported by large randomized trials and FDA warnings 6

Indicators That Step-Up Is Needed

Step up therapy if any of the following occur despite correct inhaler technique:

• SABA use >2 days/week for symptom relief (not prevention of exercise-induced bronchoconstriction) 4, 1
• Nighttime awakenings due to asthma 1
• Persistent daytime symptoms 1

Alternative First-Line Options (Less Preferred)

For patients ≥12 years with adherence concerns:

• As-needed low-dose ICS-formoterol used concomitantly with SABA is an acceptable alternative to daily low-dose ICS 1
• This provides comparable symptom control 1

Leukotriene receptor antagonists (montelukast, zafirlukast):

• Alternative but not preferred for mild persistent asthma 4, 1
• Less effective than ICS 1

Cromolyn sodium and nedocromil:

• Alternative but not preferred for mild persistent asthma 4

Common Pitfalls to Avoid

Do not increase ICS dose short-term for worsening symptoms in adherent patients ≥4 years with mild-moderate asthma, as this provides no clinical benefit 1

Verify proper inhaler technique before dose escalation, as poor technique is a common cause of apparent treatment failure 1

Do not continue high-dose ICS monotherapy if asthma remains uncontrolled after 2-6 weeks; instead, add LABA to low-dose ICS 1

Recognize reduced ICS responsiveness in:

• Smokers due to persistent irritation and scarring 1
• Black children who may have increased risk of corticosteroid insensitivity 1

Step-Down Strategy

Once asthma control is sustained for 2-4 months:

• Step down to the minimum dose required to maintain control 1
• Continue monitoring for at least 3 months of stable control before considering further dose reduction 1